Galen Growth commends each of the top 25 pharma and biotech companies for securing a position in the 2023 Digital Health Innovation Index.

The Pharmaceutical Digital Health Innovation Index assesses the Digital Health portfolios of pharmaceutical and biotech firms, with a focus on the strength of portfolio ventures as well as the alignment of portfolio ventures with strategic objectives. The 2023 edition of the Index captures the current imperative for companies to focus on improving operational efficiency using digital tools. To secure a place in the top 25, companies must have a global reach and at least 14 publicly announced partnerships with private Digital Health ventures.

Insights from the Pharmaceutical Digital Health Innovation Index:

• More biopharma companies are becoming active in Digital Health. In 2021, the top 25 biopharma companies, determined by their number of partnerships with Digital Health ventures, held 57% of all such global partnerships. However, in 2023, these leading companies’ share of partnerships has decreased to 45%.
• Since 2020, Research Solutions has emerged as the top Digital Health Cluster for partnerships with pharmaceuticals. Among the top 25 pharmaceuticals most active in partnering, 33% of the Digital Health partnerships since 2020 have focused on the Research Solutions cluster.
• 72% share of Digital Health ventures partnering with biopharma are using AI or GenAI (a subset of AI) technology. While AI is critical for understanding and learning from large data sets, GenAI systems can be implemented to help identify new drug targets and design new drugs, by simulating molecular interactions and predicting possible drug candidates

Read again: 2022 Pharmaceutical Digital Health Innovation Index

This report is the 3rd edition of our Pharmaceutical Digital Health Innovation Index. You can download our last years comprehensive report, capturing insights from the 2022 edition on our Research page.

Missed our last report?